As part of its ongoing attempts to penetrate the emerging markets, GlaxoSmithKline has signed an innovative pneumococcal vaccines deal in Brazil, which also includes a technology transfer and R&D investment. As well as boosting the pharma giant's volume in this rapidly growing and commercially attractive market, the deal is expected to increase access to vaccines in the country.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions